In vivo-matured Langerhans cells continue to take up and process native proteins unlike in vitro-matured counterparts.
about
Langerhans cells and dermal dendritic cells capture protein antigens in the skin: possible targets for vaccination through the skin.Sphingosine 1-phosphate modulates antigen capture by murine Langerhans cells via the S1P2 receptor subtype.Dendritic cell maturation in active immunotherapy strategies.Antigen presentation to naive CD4 T cells in the lymph node.Skin langerin+ dendritic cells transport intradermally injected anti-DEC-205 antibodies but are not essential for subsequent cytotoxic CD8+ T cell responsesMaturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity.Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens.Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skinDemystifying the development of dendritic cell subtypes, a little.Visualizing dendritic cell migration within the skin.Cutting edge: migration of langerhans dendritic cells is impaired in autoimmune dermatitisTherapeutic potential of semi-mature dendritic cells for tolerance induction.HIV transmission: migratory Langerhans cells are primary targets in vaginal HIV transmission.Salmonella infection of afferent lymph dendritic cells.Mature DC from skin and skin-draining LN retain the ability to acquire and efficiently present targeted antigen
P2860
Q34130289-7612CD03-BB2F-4E56-8F2F-EDB7639C9105Q34474499-7A9BDEAD-E360-4B04-BD0F-A14679A1EEA7Q34482055-65831A40-0341-491C-92F7-3AE8A44F3E5DQ35187925-9BA10FAC-841D-46FE-AC44-A85CA9A255ADQ35785681-EEF1734E-1AC5-4996-953C-FB7DA35384FCQ36088964-D066D76E-C55D-46DD-B71E-CAB95AB4B5DEQ36140598-99BEEEEF-C30F-4167-83F6-77BB5C8EEFF5Q36376581-450E3F13-2BF1-463C-B755-BD181FAF08DDQ37139265-AA037DA0-B2F5-4A58-992E-0D2E1AFF1D90Q37318829-C9D89BAC-4314-47FE-9068-04FECF5D55DEQ37398202-57CC8CC5-E132-4975-BA52-6CD198E356ACQ39613283-8CA8E7DB-BEC2-4BA3-8FD1-8101CAB3A9CBQ46351420-14F11E6C-A7D7-47EB-B562-96A1F4B89036Q50067014-3E9D143B-B199-4D1A-A814-2CBAFCEEFF60Q57275440-3819CB80-8044-4A49-BC2E-C5CA77EC9050
P2860
In vivo-matured Langerhans cells continue to take up and process native proteins unlike in vitro-matured counterparts.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
In vivo-matured Langerhans cel ...... in vitro-matured counterparts.
@en
In vivo-matured Langerhans cel ...... in vitro-matured counterparts.
@nl
type
label
In vivo-matured Langerhans cel ...... in vitro-matured counterparts.
@en
In vivo-matured Langerhans cel ...... in vitro-matured counterparts.
@nl
prefLabel
In vivo-matured Langerhans cel ...... in vitro-matured counterparts.
@en
In vivo-matured Langerhans cel ...... in vitro-matured counterparts.
@nl
P2093
P1476
In vivo-matured Langerhans cel ...... in vitro-matured counterparts.
@en
P2093
P304
P356
10.4049/JIMMUNOL.166.12.7178
P407
P577
2001-06-01T00:00:00Z